Clinical Study on Diagnosis of Lung Cancer by Tumor Marker Test
Objective To study the clinical value of tumor markers in the diagnosis of lung cancer.Methods A total of 50 patients with lung cancer who were examined and treated in Xuzhou Hospital of Traditional Chinese Medicine,Jiangsu Province from March 2021 to February 2022 were non-randomly selected as observation group 1,and 50 pa-tients with benign lung lesions who were examined and treated in our hospital during the same period were selected as observation group 2.Another 50 healthy people who underwent physical examination during the same period were se-lected as the control group.Blood samples of three groups of subjects were selected for tumor marker detection.It mainly includes serum carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),neuron-specific enolase(NSE),cytokeratin fragment antigen 21-1(CYFRA21-1),squamous cell carcinoma antigen(SCC).The diagnostic effi-cacy of single and combined detection of the above indicators was analyzed.Results The expression levels of serum CEA,CA125,NSE,CYFRA21-1 and SCC in the observation group 1 and the observation group 2 were higher than those in the control group,and the differences were statistically significant(all P<0.05).The above indexes in the ob-servation group 1(15.45±4.16)ng/mL,(51.74±6.56)U/mL,(26.26±2.52)ng/mL,(9.63±3.24)ng/mL,(3.64±0.21)ng/mL were higher than those in the observation group 2,and the differences were statistically significant(t=8.123,6.598,8.449,5.817,45.521,all P<0.05).The sensitivity,specificity and accuracy of combined detection of 5 tumor markers were 80.0%,84.0%,82.0%,kappa=0.817.Conclusion CEA,CA125,NSE,CYFRA21-1 and SCC can be used as tumor markers for clinical diagnosis of lung cancer,and the combined detection has significant advantages.
NETL
NSTL
万方数据
